DAY 1

Sunday 10 April

OPENING CEREMONY | Room 14
  • 17.00 Welcome Addresses
    Speakers: K. Lackner (Germany), M. Neumaier (Geermany), K. Adeli (Canada), T. Ozben (Turkey), M. Nauck (Germany)
  • 17.30 Announcement of EFLM Awards
    Chair: T. Ozben (Turkey)
  • 18.00 Opening Lecture
    Where, when, and how? The Quest for Extraterrestrial Life
    Chair: M. Neumaier (Germany)
    Speaker: W. Duschl (Germany)
  • 19.00 Welcome Cocktail

DAY 2

Monday, 11 April

  • 9:00-10:00 PLENARY LECTURE | Room 1
    Chair: P. Gillery (France)
    Fine tuning of innate immunity – T. Chavakis (Germany)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 1 | Room 1
    Acute Kidney Injury biomarkers: from lab to bedsideChairs: C. Ronco (Italy), F. Alcantara (Brazil)
    The continuum of AKI and the utility of biomarkers – C. Ronco (Italy)
    New Biomarkers in AKI: application in clinical routine – L- Forni (UK)
    Prevention/protection of the kidney guided by biomarkers – M. Ostermann (UK)
    Urinary kidney injury biomarkers determined by LC-MRM-MS in health and disease – T. van Duijl (The Netherlands)
    The role of the laboratory in the early detection of acute kidney injury in hospitalised patients – P. Fernández-Riejos (Spain)
  • 10:30-12:30 SYMPOSIUM 2| Room 5
    Chronic myeloproliferative neoplasmsChairs: D. Coriu (Romania), S.N. Constantinescu (Belgium)
    Diagnostic algorithm in myeloproliferative neoplasms – D. Coriu (Romania)
    Inhibiting pathologic signaling induced by driver and epigenetic mutations in myeloproliferative neoplasms: monitoring treatment by next generation sequencing – S.N. Constantinescu (Belgium)
    Challenges of using next-generation sequencing technologies in the clinical management of myeloproliferative neoplasms – C. Mambet (Romania)
    ALNeT: a new deep learning model for the diagnosis of acute leukaemia lineage using peripheral blood cell images – J. Rodellar (Spain)
  • 10:30-12:30 SYMPOSIUM 3 | Room 13a
    Performance Specifications in Laboratory Medicine – from different models to practical useChairs: S. Sandberg (Norway), A. R. Horvath (Australia)
    Analytical performance specifications: From models to practical use – S. Sandberg (Norway)
    Outcome-based models – a link between clinical and analytical performance – A.R. Horvath (Australia)
    A practical way of calculating measurement uncertainty in laboratory medicine and compare it to APS – A. Coskun (Turkey)
    Analytical Performance Specifications Derived from Uncertainty Budgets Based on Clinical Decision Limits – E.S. Rotgers (Finland)
  • 10:30-12:30 SYMPOSIUM 4 | Room 13b
    Clinical Use Cases for Integrated diagnostics for Laboratory Medicine and RadiologyChairs: M. Fuchsjäger (Austria), M. Neumaier (Germany)
    EIBIR, a support platform for research funding in future integrative diagnostics between imaging and the laboratory – K. Krischak (Austria)
    Personalized Diagnostics in detection of recurrence of metastatic colorectal cancer – S. Schönberg (Germany)
    Prediction of prognosis based on laboratory data and chest CT – S. Cappabianca (Italy)
    Integrative diagnostics to investigate tissue damage dynamics – M. Frölich (Germany), C. Gerhards (Germany)
  • 10:30-12:30 SYMPOSIUM 5 | Room 14a
    COVID-19: biology, clinics, laboratory diagnostics and biosafety issuesChairs: G. Lippi (Italy),K. Adeli (Canada)
    Biology and clinics of COVID-19 – G. Lippi (Italy)
    Molecular and serological testing of COVID-19 – K. Adeli (Canada)
    Laboratory responsiveness to COVID-19: results of an IFCC survey – T.P. Loh (Singapore)
    Clinical laboratory testing in a pandemic: what we have learned from the COVID-19 experience – D. Koch (USA)
  • 10:30-12:30 DGKL SYMPOSIUM | Room 14c
    Metabolomics via NMR spectroscopyChairs: M. Nauck (Germany), C. Sina (Germany)
    Lipoprotein diagnostics via NMR. From research to clinical application – M. Nauck (Germany)
    NMR Metabolomics: an enabler of precision nutritio – C. Sina (Germany)
    NMR Biomarker Research: Targeted and untargeted approach – A. Petersmann (Germany)
    Association of triacylgcerol-glucose index with low-density lipoprotein particle number and size measured by proton nuclear magnetic resonance spectroscopy – O. Racz (Slovakia)
    Serum Metabolome Analysis of Iron Deficiency Anemia Patients Using Nuclear Magnetic Resonance (Quantitative Approach) – A.Z. Gul (Turkey)
  • 12:30-14:00 POSTER SESSION| Hall C1
  • 14:00-16:00 SYMPOSIUM 6 | Room 14c
    Artificial intelligence, data science and laboratory medicine: crossed destiniesChairs: D. Gruson (Belgium), M. Cowie (UK)
    The AI data wave, seizing opportunities – M. Cowie (UK)
    How to dive into large scale dataset? – B. Macq (Belgium)
    What are the keys for Europe as a space for data and AI? – Y. Tolias (Belgium)
    Round Table – M. Cowie, B. Macq, Y. Tolias
  • 15:30-16:30 VIEWPOINT 1 | Room 1
    Is eGFR the gold standard for evaluating renal dysfunction?Chair: K. Makris (Greece)
    Measuring GFR–tohubohu – E. Schaeffner (Germany)
    Estimating eGFR: no blind trust – P. Delanaye (Belgium)
  • 17:00-18:00 VIEWPOINT 2 | Room 1
    Quantitative mass spectrometry vs immunoassays of clinically relevant peptides and proteins.Chair: C. Cobbaert (Netherlands)
    Can quantitative mass spectrometry replace immunoassays for blood proteins? The only question is when? – C. Borchers (Canada)
    Quantitative mass spectrometry cannot replace immunossays for blood proteins – S. Lehmann (France)

DAY 3

Tuesday, 12 April

  • 9:00-10:00 PLENARY LECTURE | Room 1
    Chair: K. Lackner (Germany)
    Biomarkers for cardiovascular risk stratification – S. Blankenberg (Germany)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 7 | Room 1
    Implementation of Liquid Biopsy
    Chairs: M. Neumaier (Germany), V. Haselmann (Germany)
    European Liquid Biopsy Society: From Discovery to Clinical Implementation of Liquid Biopsy Analyses – K. Pantel (Germany)
    Latest development in Liquid Profiling – N. Papadopoulos (USA)
    HTA of clinical decision-making of circulating nucleic acids in cancer patients – M. IJzerman (Australia)
    The importance of Integrative molecular analysis in Liquid biopsies – E. Lianidou (Greece)
  • 10:30-12:30 SYMPOSIUM 8 | Room 5
    New approaches for determining reference intervals across all agesChairs: Y. Ozarda (Turkey), T. Streichert (Germany)
    Comparison of different approaches for deriving reference intervals – Y. Ozarda (Turkey)
    Age related RIs: Methods for continuous RIs and possible applications – T. Streichert (Germany)
    A new computer-intensive approach for the indirect derivation of reference intervals – K. Ichihara (Japan)
    Pediatric Reference Intervals for Trace Elements in the CALIPER cohort of healthy children and adolescents using ICP-MS/MS and HR-MS Technology – M. K. Bohn (Canada)
    NUMBER-2: The automation and extension to routine haematology of the Dutch indirect data-mining approach to establish population-specific reference intervals – N. Brouwer (The Netherlands)
  • 10:30-12:30 SYMPOSIUM 9 | Room 13a
    New insights in amyloidosisChairs: G. Palladini (Italy), S.O. Schönland (Germany)
    The clinical laboratory in the management of systemic amyloidosis: state of the art – G. Palladini (Italy)
    Genetics of the amyloidogenic plasma cell clone: impact on clinical management – S.O. Schönland (Germany)
    Assessment of MRD in AL amyloidosis – B. Paiva (Spain)
  • 10:30-12:30 SYMPOSIUM 10 | Room 13b
    How to make EQA fit for purpose?Chairs: P. Meijer (Netherlands), C. Buchta (Austria)
    What are the fundamental aims of EQA? – C. Buchta (Austria)
    The role of EQA in quality assurance of the extra-analytical phase – J. Cadamuro (Austria)
    Patient results for “real-time” surveillance of pre-analytical and analytical stability – A.E. Solsvik (Norway)
    Development of an External Quality Assessment (EQA) Programme for SARS-CoV-2 Ab – A. Thomas (UK)
    Assessing laboratory performance of hs-c-troponin with EQA data – M. van Schrojenstein Lantman (The Netherlands)
  • 10:30-12:30 SYMPOSIUM 11 | Room 14a
    HemostasisChairs: B. Lammle (Germany), K. Vanhoorelbeke (Belgium)
    Procoagulant COAT platelets: Mechanisms and clinical relevance – L. Alberio (Switzerland)
    Monitoring of novel therapies of hemophilia in the clinical laboratory – S. Kitchen (UK)
    Thrombotic thrombocytopenic purpura – from bench to bedside – K. Vanhoorelbeke (Belgium)
    Diagnosis and laboratory-guided clinical management of anticoagulant rodenticides poisoning – M. Lenski (France)
    Multicentre study on the comparison of methods for the measurement of anticoagulant activity in patients treated with DOAC (Direct Oral AntiCoagulants) – M. Vidali (Italy)
  • 10:30-12:30 DGKL SYMPOSIUM | Room 14c
    Autoimmune disorders of coagulationChairs: K. Lackner (Germany), U. Sachs (Germany)
    How to Diagnose Immune Thrombocytopenia – U. Sachs (Germany)
    Pathophysiology and Diagnosis of Antiphospholipid Syndrome – N. Müller-Calleja (Germany)
    Acquired hemophilia – diagnosis and treatment – A. Tiede (Germany)
  • 12:30-14:00 POSTER SESSION | Hall C1
  • 14:00-16:00 SYMPOSIUM 12 | Room 14c
    New development in Diagnosis and therapy of dyslipidemia and CVDChairs: B. Nordestgaard (Denmark), A. von Eckardstein (Switzerland)
    Advances in lipid-lowering therapy through antibody-based and gene-silencing technologies – B. Nordestgaard (Denmark)
    Measuring atherogenic lipoproteins that address residual cardiovascular risk beyond LDL-c – M. Langlois (Belgium)
    The challenges of measuring apolipoprotein(a) and its relevance for patient management and patient outcome – C. Cobbaert (Netherlands)
    HDL-Quo vadis? – A. von Eckardstein (Switzerland)
  • 15:30-16:30 VIEWPOINT 3 | Room 1
    Biomarkers of alcohol abuse in clinical and forensic use – strengths and limitationsU. Ceglarek (Germany)
    Carbohydrate deficient transferrin as marker for alcoholism, its use in comparison with ‘old’ indirect biomarkers – JPM. Wielders (Netherlands)
    Ethylglucuronide (EtG) – the one and only (direct) marker of alcohol consumption? – H. Andresen-Streichert (Germany)
  • 17:00-18:00 VIEWPOINT 4 | Room 1
    Which future for HbA1c as biomarker of diabetes monitoring?Chair: E. Kilpatrick (UK)
    HbA1c remains the gold standard – G. John (UK)
    The future belongs to Time in Range and continuous glucose monitoring indications – D. Leslie (UK)

DAY 4

Wednesday, 13 April

  • 9:00-10:00 PLENARY LECTURE | Room 1
    Chair: M. Neumaier (Germany)
    Integrative Diagnostics as the Key Driver for Intelligent Systems in Medicine – S. Schönberg (Germany)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 13 | Room 13a
    Porphyrias – integration of laboratory medicine and clinical care (A symposium in memorial of the 140 years anniversary of the birth of Hans Fischer)Chairs: S. Sandberg (Norway), A.K. Aarsand (Norway)
    Hans Fischer and his role in developing the field of porphyria – S. Sandberg (Norway)
    Practical guidelines on how to diagnose the porphyrias – A.K. Aarsand (Norway)
    Regulation of the haem biosynthesis – J. Philips (USA)
    Newer treatment options for porphyria – J.-C. Deybach (France)
  • 10:30-12:30 SYMPOSIUM 14 | Room 5
    Advances in IQC tools and techniquesChairs: T. Badrick (Australia), E. Kilpatrick (UK)
    How is conventional QC practised now and how can it be improved? – E. Kilpatrick (UK)
    The importance of demonstrating commutability of reference materials with IQC – V. Delatour (France)
    Patient Based Real Time QC – an introduction – T. Badrick (Australia)
    PBRTQC – implementing into routine practice – validation and simulation – A. Bietenbeck (Germany)
  • 10:30-12:30 SYMPOSIUM 15 | Room 1
    High-sensitivity troponins and beyondChairs: S. Wittfooth (Finland), R. Christenson (USA)
    Analytical aspects of high-sensitivity troponin assays: Impact on Clinical Application – Robert Christenson (US)
    High-sensitivity troponins in clinical use – Paul Collinson (GB)
    Troponin fragments for better specificity? – Saara Wittfooth (FI)
  • 10:30-12:30 SYMPOSIUM 16 | Room 13b
    Health platforms of the future and clinical relevance of interoperability – Chair: C. Cobbaert (Netherlands)
    Defining Interoperability in Healthcare with HL7-FHIR and understanding the potential transformation of pathology – G. Grieve (Australia)
    The value of interoperable communication of pathology requests and results – K. Sikaris (Australia)
    Illuminating the Black Box – why and how to do explainable Artificial Intelligence in a medical setting – A. Tolios (Austria)
  • 10:30-12:30 SYMPOSIUM 17 | Room 14a
    New trends in standardizationChairs: P. Gillery (France), E. Cavalier (Belgium)
    Standardization of bone markers – E. Cavalier (Belgium)
    Standardization in fecal immuno-testing – S. Benton (UK)
    Traceability chains in Therapeutic drug monitoring: scope, limitations and state of the art – C. Seger (Switzerland)
    Standardization in glucose monitoring – G. Freckmann (Germany)
  • SYMPOSIUM DGKL | Room 14c
    Personalised medicine in allergy diagnosticsChair: Harald Renz (DE)
    Molecular Diagnosis and Digital Health for Precision Allergology – Paolo Maria Matricardi (IT)
    Asthma and COPD diagnostics – lessons learned from multi-centre big data analysis – Harald Renz (DE)
    The Janus-faced nature of viral infections in asthma – Chrysanthi Skevaki (DE)
    Chip-based diagnosis for personalized treatment – Katarzyna Niespodziana (AT)
  • 12:30-14:00 POSTER SESSION | Hall C1
  • 14:00-16:00 SYMPOSIUM 18 | Room 14c
    Consequences of IVDR Regulations on Laboratory MedicineChairs: C. Cobbaert (Netherlands), P- Monaghan (UK)
    The in Vitro Diagnostics Regulation – the perspective of the European Commission – O. Tkachenko (Belgium)
    Consequences of the IVDR 2017/746 for the IVD-industry – O. Bisazza (Belgium), I. Slobodeaniuc (Belgium)
    Consequences of the IVDR 2017/746 for Notified Bodies – A.F. Stange (Japan)
    Consequences of the IVDR 2017/746 for Laboratory Professionals – C. Cobbaert (Netherlands)
  • 15:30-16:30 VIEWPOINT 5 | Room 1
    What should be the lipid profile in the era of personalized cardiovascular risk assessment and treatment?Chair: M. Langlois (Belgium)
    Current status for lipid profiles for cardiovascular risk assessment – M. Langlois (Belgium)
    Assessment of traditional risk factors including a non-fasting lipid profile is no longer the most rational approach for cardiovascular risk assessment and treatment – B. Nordestgaard (Denmark)
  • 17:00-18:00 VIEWPOINT 6 | Room 1
    Regulating direct-to-consumer testing 2.0: Protecting the consumerChair: B. Gouget (France)
    Introduction: What is Direct-to-Consumer (D2C or DTC), how to increase Public Awareness – B. Gouget (FR)
    Opportunities for decentralized testing in modern healthcare and dangers vs benefits of DTC – J.H. Nichols (USA)
    Advocacy for appropriate regulation of biological tests sold directly to consumers – M. Vaubourdolle (France)

DAY 5

Thursday, 14 April

  • 9:00-10:00 PLENARY LECTURE | Room 1
    Chair: K. Adeli (Canada)
    Towards next generation diagnostics by X-omics – A. Van Gool (Netherlands)
  • 10:00-10:30 Break
  • 10:30-12:30 SYMPOSIUM 19 | Room 14a
    New diagnostic approaches in Laboratory MedicineChairs: M. Plebani (Italy), S. Bernardini (Italy)
    Extracellular vesicles in clinical diagnostics – K. Witwer (USA)
    miRNA in clinical diagnostics – can artificial intelligence make the difference? – A. Keller (Germany)
    Wearable biosensors – W. Gao (USA)
    Comparison of reference values for small extracellular particles in a healthy study cohort using Nanoparticle Tracking Analysis (NTA) before and after particle isolation by different isolation methods – B. Betz (Germany)
    Analysis of volatile organic compounds (VOCs) in the breath of colorectal cancer (CRC) subjects by Cyranose ‘electronic nose – S. Rapi (Italy)
  • 10:30-12:30 SYMPOSIUM 20 | Room 5
    Autoimmune EncephalitisChairs: A. Vincent (UK), L. Tebartz van Elst (Germany)
    Overview and pathophysiology – A. Vincent (UK)
    Autoimmune encephalopathies in Neurology – M. Gastaldi (Italy)
    Autoimmune encephalopathies in Psychiatry – L. Tebartz van Elst (Germany)
    10:30-12:30 SYMPOSIUM 21 | Room 13a
    Urinalysis: a new look at old testsChairs: J. Delanghe (Belgium) – W. Hofmann (Germany)
    Modern urine test strip technology – J. Delanghe (Belgium)
    Automated urinalysis – G. Previtali (Italy)
    The Revised European Urinalysis Guidelines – T. Kouri (Finland)
    New approaches to the study bladder cancers using molecular genetic methods and fluorescence analysis – K. Dubayová (Slovakia)
  • 10:30-12:30 SYMPOSIUM 22 | Room 13b
    Young Scientist SessionChairs: S. Fares Taie (Argentina), R. Sierra Amor (Mexico)
    Motivation in the Clinical Laboratory – S. Fares Taie (Argentina)
    Time Management Tools for the Young Laboratory Professional – J. El-Khoury (USA)
    Career management for Young Laboratory Scientists – G. Sancesario (Italy)
    Conflict Management amongst Young Laboratory Scientists – T. Pillay (South Africa)
  • 10:30-12:30 SYMPOSIUM 23 | Room 1
    How does Point of Care Testing change the clinical pathways?Chairs: A. Khan (USA), A. Stavelin (Norway)
    Point-of-care Testing: a win-win for all players – A. Khan (USA)
    Is internal (and external?) quality control necessary for POCT? – A. Stavelin (Norway)
    The role of POC-testing in the clinical pathway of diagnosing SARS-CoV-2 infection – M.C. Tollanes (Norway)
    Testing for Anti-Mullerian Hormone: analytical performances and usability of a Point-of-Care assay – D. Gruson (Belgium)
    Hemolysis detection with the H-10 Hemcheck device in whole blood and plasma STAT samples – A. Garcia Osuna (Spain)
  • 10:30-12:30 DGKL SYMPOSIUM | Room 14c
    Emerging infectious diseases – impact of laboratory diagnosis – Chair: M. Klouche (Germany)
    Infectious disease emergency preparedness and prevention – J. Vila (Spain)
    Infectious disease surveillance – implications of diagnostic screening strategies – R. Dürrwald (Germany)
    High-throughput LAMP-sequencing for diagnosis of infectious diseases – J. Schmid-Burgk (Germany)
    Setting up external quality control measures for SARS-CoV-2 during pandemics – V. Haselmann (Germany)
  • 12.30 – 13.30  CLOSING CEREMONY | Room 1
    Closing Remarks
    Speakers: K. Lackner (Germany), M. Neumaier (Germany), K. Adeli (Canada), T. Ozben (Turkey)
    Presentation of 3rd EFLM Strategic Conference
    T. Ozben (TR), President of the Conference
    Presentation of WorldLab-Euromedlab Roma 2023
    S. Bernardini (Italy), President of the congress